SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD

Andreas Stahl; C. Lange; Clare Bailey; Vasileios Konidaris; Varun Chaudhary; Paolo Lanzetta; Hassiba Oubraham; Martin Kirchner; Tobias Machewitz; Sarah Schlief; Susanne Oesch; Peter Morgan-Warren; Marion Munk; Aude Ambresin

doi:10.3205/26doc132

June 17, 2026Open Access

SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the effectiveness and safety of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD) in different patient groups.
Ongoing interventional study (SPECTRUM, NCT06075147) evaluating aflibercept 8 mg
Patients included: treatment-naïve and previously treated individuals with nAMD
Assessment of Week 24 data
Improvements were observed in treatment-naïve patients receiving aflibercept 8 mg
Stable outcomes were noted in patients previously treated for nAMD

Implication

Demonstrates improvement in treatment-naïve patients with nAMD, suggesting effective therapy options.

Abstract

Purpose: To present Week (W) 24 results from the SPECTRUM study on the real-world effectiveness and safety of aflibercept 8 mg in patients with treatment-naïve (TN) and previously treated (PT) neovascular age-related macular degeneration (nAMD). Methods: SPECTRUM (NCT06075147) is an ongoing, [for full text, please go to the a.m. URL]

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stahl et al. (2026) studied this question.

synapsesocial.com/papers/6a34de7065a5b0777af2dd9e https://doi.org/10.3205/26doc132

View Full Paper

Ask AI

Bookmark

Share

SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD

Key Points

Implication

Abstract

Discussion

Cite This Study

SPECTRUM: Week 24 data for aflibercept 8 mg indicate improvements in patients with treatment-naïve nAMD and stable outcomes in patients with previously treated nAMD

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading